BEST Inc.

    BEST Inc.

    NNYSE:BEST
    2.78
    USD
    -0.02
    (-0.71%)
    2014 Y
    2015 Y
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    TTM
    Revenue per Share
    162.39
    278.41
    468.45
    1,067.49
    1,296.58
    538.21
    545.58
    574.86
    389.62
    436.04
    426.97
    Basic EPS, GAAP
    -41.27
    -71.83
    -103.2
    -65.57
    -26.22
    -10.39
    -104.96
    13.18
    -73.62
    -42.7
    -36.54
    Free Cash Flow per Basic Share
    -28.83
    -39.1
    -72.51
    -78.67
    -102.33
    -10.39
    -29.96
    -152.4
    -65.09
    -37.17
    -26.01
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    - -
    -426.06
    -723.22
    -793.64
    -794.66
    -801.26
    -916.44
    -877.74
    -951.36
    -1,034.18
    -993.83
    Tangible Book Value per Share
    - -
    -438.14
    -729.29
    202.15
    182.09
    185.15
    84.29
    106.01
    33.91
    -11.39
    -18.83
    Basic Weighted Avg Shares
    19
    19
    19
    19
    19
    19
    19
    20
    20
    19
    20
    Sales/Revenue/Turnover
    3,066
    5,256
    8,844
    19,990
    25,116
    10,481
    10,528
    11,426
    7,744
    8,316
    8,543
    Operating Margin (%)
    -23.59
    -20.7
    -15.83
    -6.39
    -1.02
    -4.21
    -9.23
    -12.8
    -18.42
    -10.31
    -9
    Depreciation Expense
    85
    147
    246
    364
    441
    150
    157
    191
    189
    189
    - -
    Net Income, GAAP
    -718
    -1,059
    -1,363
    -1,228
    -508
    -202
    -2,026
    262
    -1,463
    -814
    -731
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    -23.43
    -20.16
    -15.42
    -6.14
    -2.02
    -1.93
    -19.24
    2.29
    -18.9
    -9.79
    -8.56
    Working Capital
    - -
    -1,424
    809
    1,579
    -284
    -881
    -3,267
    992
    -935
    -1,762
    -1,672
    LT Debt
    - -
    - -
    8
    2
    1
    4,751
    3,733
    3,251
    2,770
    1,448
    1,204
    Total Equity
    - -
    -8,027
    -13,508
    4,392
    4,140
    3,915
    1,725
    2,217
    804
    -70
    -231
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    CNY

    •

    in mil. unless spec.
    Sep'23
    Dec'23
    Mar'24
    ST Debt
    1,541
    1,828
    2,075
    LT Borrowings
    964
    585
    426
    LT Finance Leases
    23
    864
    778
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    398
    404
    404
    Market Capitalization
    322
    360
    318

    Working Capital

    CNY

    •

    in mil. unless spec.
    Sep'23
    Dec'23
    Mar'24
    Total Current Assets
    2,396
    3,090
    3,235
    Cash, Cash Equivalents & STI
    519
    462
    295
    Accounts Receivable, Net
    870
    1,078
    751
    Inventories
    10
    8
    8
    Total Current Liabilities
    4,473
    4,852
    4,907
    Payables & Accruals
    2,653
    2,415
    2,545
    ST Debt
    1,541
    1,828
    2,075
    Deferred Revenue
    280
    469
    287

    Growth Rates

    CNY

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    -41.06%
    -108.7%
    Free Cash Flow
    - -
    83.44%
    -45.21%
    Net Income, GAAP
    - -
    4.91%
    -44.35%
    Sales/Revenue/Turnover
    - -
    -14.83%
    7.38%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    CNY

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    1,803
    1,931
    2,029
    1,981
    7,744
    2023
    1,715
    2,138
    2,227
    2,236
    8,316
    2024
    1,942
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    CNY

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    -18.44
    -16.75
    -19.23
    -22.19
    -73.62
    2023
    -12.4
    -7.31
    -8.96
    -12.23
    -42.7
    2024
    -8.01
    - -
    - -
    - -
    - -

    Quarterly Dividends Per Share

    CNY

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • globenewswire.com

      Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026

    • prnewswire.com

      CARNIVAL CORPORATION OUTPERFORMS GUIDANCE, DELIVERING BEST EVER REVENUES, NET YIELDS AND NET INCOME

    • prnewswire.com

      TRAVEL + LEISURE BRINGS WORLD'S BEST SUMMIT TO LONDON FOR FIRST INTERNATIONAL EDITION

    • seekingalpha.com

      Opus Genetics: A Resounding Study Success Merits A Higher Valuation

    • seekingalpha.com

      Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial Transcript

    • globenewswire.com

      Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

    • gurufocus.com

      BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion

    • businesswire.com

      BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion

    • globenewswire.com

      Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences

    • gurufocus.com

      Bruker Reports Second Quarter 2026 Financial Results

    • gurufocus.com

      FreeCast Announces FreeCast Cities™, a Free Local Streaming Platform Designed for All 210 U.S. Television Markets

    • globenewswire.com

      Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

    • newsfilecorp.com

      OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program

    • prnewswire.com

      NEVADA KING GRADUATES TO THE PREMIUM OTCQX BEST MARKET, ENHANCING VISIBILITY FOR U.S. INVESTORS

    • prnewswire.com

      S&T BANK NAMED A FORBES AMERICA'S BEST-IN-STATE BANK FOR 2026

    • prnewswire.com

      IN A SALUTE TO AMERICA'S 250TH BIRTHDAY, SEAWORLD PARKS LAUNCH THEIR BEST OFFER OF THE YEAR WITH THE FOURTH OF JULY SALE

    • prnewswire.com

      IN A SALUTE TO AMERICA'S 250TH BIRTHDAY, BUSCH GARDENS LAUNCHES ITS BEST DEAL OF THE YEAR WITH THE FOURTH OF JULY SALE

    • prnewswire.com

      KIA EARNS FOUR HONORS IN U.S. NEWS & WORLD REPORT'S 2026 "BEST ADVENTURE VEHICLES" AWARDS

    • marketbeat.com

      Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst

    • prnewswire.com

      2027 KIA TELLURIDE NAMED BEST THREE-ROW FAMILY SUV BY THE NORTHWEST AUTOMOTIVE PRESS ASSOCIATION (NWAPA)